Several other targets of interest such as insulin-like growth factor receptor 1 (IGF-1R), receptor tyrosine kinase-like orphan receptor 1 (ROR1), and Ephrin type-A receptor 2 (EphA2) are overexpressed in various sarcomas and few CAR T-cell therapy clinical studies are currently ongoing. Here, ROR1 is linked to sarcoma.